1. lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition by sponging miR-125a-5p and upregulating ANLN and RRM2
    Qijun Cao et al, 2024, Acta Biochimica et Biophysica Sinica CrossRef
  2. Long non-coding RNA LINC00152 in cancer: Roles, mechanisms, and chemotherapy and radiotherapy resistance
    Shuang Li et al, 2022, Frontiers in Oncology CrossRef
  3. The crosstalking of lactate‐Histone lactylation and tumor
    Yao Rong et al, 2023, PROTEOMICS – Clinical Applications CrossRef
  4. Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
    Xiaoyu Deng et al, 2021, Frontiers in Molecular Biosciences CrossRef
  5. The Role of Non-Coding RNAs in Breast Cancer Drug Resistance
    Jin-hai Tian et al, 2021, Frontiers in Oncology CrossRef
  6. Downregulation of the long noncoding RNA DSCR9 (Down syndrome critical region 9) delays breast cancer progression by modulating microRNA-504-5p-dependent G protein-coupled receptor 65
    Mingzhu Li et al, 2023, Human Cell CrossRef
  7. From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells
    Jéssica Fernanda Barazetti et al, 2021, Cancers CrossRef
  8. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
    Xuehao Zhou et al, 2022, Frontiers in Oncology CrossRef
  9. miR-145-3p Hampers the Malignant Progression of Esophageal Carcinoma via CXCL5 Downregulation
    Gang Chen et al, 2022, Analytical Cellular Pathology CrossRef
  10. An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer
    Ya-Wen Wang et al, 2023, Aging CrossRef
  11. Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer
    Toshihiko Takeiwa et al, 2020, Cancers CrossRef
  12. DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer
    Xiaoli Liang et al, 2022, Molecular Biology Reports CrossRef
  13. LINC00152 Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma
    Rossella Pellegrino et al, 2022, Cells CrossRef
  14. Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer
    Mengwei Wang et al, 2021, OncoTargets and Therapy CrossRef
  15. Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
    Jing Chen et al, 2021, Cancer Cell International CrossRef
  16. ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer
    Hyeon Woo Kim et al, 2023, Epigenetics CrossRef
  17. Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
    Penn Muluhngwi et al, 2021, Cancers CrossRef
  18. Roles of zinc in cancers: From altered metabolism to therapeutic applications
    Mohamed Bendellaa et al, 2024, International Journal of Cancer CrossRef

  19. Long Non-Coding RNAs in Drug Resistance of Breast Cancer


    Tonghua Du et al, 2020, OncoTargets and Therapy CrossRef
  20. Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC
    Yichen Song et al, 2022, Journal of Oncology CrossRef
  21. Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
    Monica Cantile et al, 2020, Cancers CrossRef
  22. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration
    Jianwei Wang et al, 2022, Frontiers in Cellular and Infection Microbiology CrossRef